Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancer.
about
Capecitabine or infusional 5-fluorouracil for gastroesophageal cancer: a cost-consequence analysis.Challenges of drug resistance in the management of pancreatic cancer.Recommendations and expert opinion on the adjuvant treatment of colon cancer in Spain.Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: implications for health-care utilization in Australia.
P2860
Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Economic evaluation of capecit ...... therapy in colorectal cancer.
@en
Economic evaluation of capecit ...... therapy in colorectal cancer.
@nl
type
label
Economic evaluation of capecit ...... therapy in colorectal cancer.
@en
Economic evaluation of capecit ...... therapy in colorectal cancer.
@nl
prefLabel
Economic evaluation of capecit ...... therapy in colorectal cancer.
@en
Economic evaluation of capecit ...... therapy in colorectal cancer.
@nl
P2860
P356
P1476
Economic evaluation of capecit ...... therapy in colorectal cancer.
@en
P2093
Jennie H Best
Louis P Garrison
P2860
P304
P356
10.1586/ERP.10.12
P577
2010-04-01T00:00:00Z